The SAMe-TT2R2 score is a clinical prediction rule to predict the quality of vitamin K antagonist anticoagulation therapy as measured by time in therapeutic INR range (TTR). It has been suggested that it can aid in the medical decision making between VKAs and new oral anticoagulant/non-VKA oral anticoagulant in patients with atrial fibrillation. This score can be used with patients with >=1 additional stroke risk factors using the CHA2DS2-VASc score, where oral anticoagulation is recommended or should be considered.

This score reflects the need to offer an improved patient care pathway when using oral anticoagulants. While NOACs avoid the need for drug monitoring, they have an unstable bioavailability and are not indicated for patients with chronic renal failure or in patients with valvular replacement surgery.

SAMe-TT2R2 score-screen-shot-2017-04-27-at-3-59-31-pm-png

SAMe-TT2R2 score-screen-shot-2017-04-27-at-4-00-40-pm-png